BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...

Youdao, Inc. ("Youdao" or the "Company") (NYSE: DAO), an intelligent learning company with industry-leading technology ...

The deal is set for completion in Q1 2025. Credit: afotostock via Shutterstock. BioNTech has signed a definitive agreement to ...

Mediterranean chain Cava raised full-year outlook as well. Q3 sales jumped 39%, accelerating from Q2's pace. Shares of Cava ...

BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a ...

BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Cash generation is up 4% compared to September 2023, and net debt has fallen 89 million in the past year - Subscription models continue to drive growth and digital transformation: Santillana reports ...

Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...